Intuitive Surgical shares surge after crushing earnings expectations

Intuitive Surgical (ISRG) shares surged over 17% after reporting third-quarter results that significantly exceeded analyst expectations, driven by robust procedure growth and accelerated adoption of its da Vinci 5 system. The company posted adjusted EPS of $2.40 and revenue of $2.51 billion, both beating consensus estimates, with worldwide procedures growing 20% and da Vinci 5 placements more than doubling. ISRG also repurchased $1.92 billion in shares and maintained its 2025 da Vinci procedure growth guidance, leading Leerink Partners to reiterate an Outperform rating and raise its price target, signaling continued confidence in its market position and growth trajectory.

Analysis

Intuitive Surgical Inc. (ISRG) significantly exceeded third-quarter analyst expectations, driving its shares up over 17% post-earnings. The company reported adjusted earnings of $2.40 per share, handily beating the $1.99 estimate, while revenue jumped 23% year-over-year to $2.51 billion, surpassing the $2.41 billion consensus. This strong performance was primarily fueled by robust worldwide procedure growth of approximately 20% and accelerating adoption of its newest da Vinci 5 system.

Procedure growth was notable, with da Vinci procedures increasing 19% and Ion procedures surging 52%. The company placed 427 da Vinci systems, including a more than doubling of da Vinci 5 placements to 240 units, contributing to a 13% year-over-year increase in the total installed base to 10,763 systems. This strong system adoption translated into a 20% increase in high-margin instruments and accessories revenue to $1.52 billion, alongside a 33% jump in systems revenue to $590 million.

Intuitive Surgical maintained its full-year 2025 guidance for da Vinci procedure growth at 17% to 17.5%, signaling continued confidence in its market trajectory. The company also demonstrated strong financial health and investor commitment by repurchasing 4.0 million shares for $1.92 billion. Leerink Partners reinforced this positive outlook, reiterating an Outperform rating and raising its price target to $600 from $593, citing strong fundamentals and operational execution.

Key Decisions for Investors

• The strong earnings beat, robust procedure growth, and positive guidance suggest continued operational momentum for ISRG, warranting a positive re-evaluation of the stock's potential.
• The significant share repurchase program and analyst price target increase indicate strong management and market confidence, reinforcing the company's long-term growth prospects.
• Investors should monitor the sustained adoption rate of the da Vinci 5 system and the growth in instruments and accessories revenue as key indicators of long-term profitability and market penetration.